#METABOLOMICS WORKBENCH hormel101_20180414_083121 DATATRACK_ID:1374 STUDY_ID:ST000958 ANALYSIS_ID:AN001572 PROJECT_ID:PR000659
VERSION             	1
CREATED_ON             	April 19, 2018, 10:26 pm
#PROJECT
PR:PROJECT_TITLE                 	Mayo Pilot and Feasibility: The Influence of Sugar, Artificial Sweeteners, and
PR:PROJECT_TITLE                 	the Microbiome on Metabolism
PR:PROJECT_SUMMARY               	As diabetes becomes a growing heath concern, afflicting nearly 25.8 million
PR:PROJECT_SUMMARY               	people in the United States and nearly 220 million people worldwide, there has
PR:PROJECT_SUMMARY               	been an increased awareness of environmental factors like diet that are
PR:PROJECT_SUMMARY               	contributing to the disease. In diabetic patients, a major causal factor
PR:PROJECT_SUMMARY               	contributing to progression of the disease is hyperglycemia, although the
PR:PROJECT_SUMMARY               	underlying mechanisms by which hyperglycemia impairs homeostatic processes are
PR:PROJECT_SUMMARY               	not well understood. While we know that early intensive glycemic control reduces
PR:PROJECT_SUMMARY               	the risk of cardiovascular complications in humans and rodent models, there is a
PR:PROJECT_SUMMARY               	large gap in studies of the etiology of hyperglycemia-induced alterations in the
PR:PROJECT_SUMMARY               	disease. To combat high sugar diets that could contribute to diabetes and
PR:PROJECT_SUMMARY               	subsequent hyperglycemia, non-caloric artificial sweeteners have become one of
PR:PROJECT_SUMMARY               	the most utilized food additives worldwide due to their consideration as a low
PR:PROJECT_SUMMARY               	caloric substitute. However, supporting scientific data as to the safety of
PR:PROJECT_SUMMARY               	these non-caloric artificial sweeteners is limited and controversial. The
PR:PROJECT_SUMMARY               	negative implications of consuming a high sugar diet on overall health have long
PR:PROJECT_SUMMARY               	been linked to diabetes, obesity, and resulting systemic health problems;
PR:PROJECT_SUMMARY               	however, it was not until recently that the negative impact of consuming
PR:PROJECT_SUMMARY               	artificial sweeteners in the place of sugar had been increasingly recognized.
PR:PROJECT_SUMMARY               	Recent evidence also suggests that a diet rich in artificial sweeteners can
PR:PROJECT_SUMMARY               	induce glucose intolerance through the alteration of the gut microbiome. We
PR:PROJECT_SUMMARY               	hypothesize that a specific subset of plasma metabolites are generated as a
PR:PROJECT_SUMMARY               	result from a diet rich in commonly used artificial sweeteners and their
PR:PROJECT_SUMMARY               	subsequent processing by the gut microbiome, which could ultimately lead to
PR:PROJECT_SUMMARY               	impaired glycemic control and negative physiological health outcomes. To test
PR:PROJECT_SUMMARY               	this hypothesis this study will 1) administer a diet high in glucose, fructose,
PR:PROJECT_SUMMARY               	and 4 common artificial sweeteners separately to rats followed by a plasma
PR:PROJECT_SUMMARY               	metabolic analysis (AIM 1) and 2) treat the gut microbiota with antibiotics in
PR:PROJECT_SUMMARY               	these animals to observe how alterations of the microbiome influence the plasma
PR:PROJECT_SUMMARY               	metabolic profile in animals receiving the altered diets (AIM 2). The resulting
PR:PROJECT_SUMMARY               	data will give us insights into the influence of high sugar and artificial
PR:PROJECT_SUMMARY               	sweetener diets on homeostatic metabolic processes and dive into the symbiotic
PR:PROJECT_SUMMARY               	relationship of the gut microbiome with this process. This data will provide
PR:PROJECT_SUMMARY               	crucial insights into the dietary use of artificial sweeteners in the
PR:PROJECT_SUMMARY               	replacement of sugars and how it alters metabolic pathways that could
PR:PROJECT_SUMMARY               	potentially lead to altered states of obesity, diabetes, and cardiovascular
PR:PROJECT_SUMMARY               	disease.
PR:INSTITUTE                     	Mayo Clinic
PR:LAST_NAME                     	Hoffmann
PR:FIRST_NAME                    	Brian
PR:ADDRESS                       	8701 Watertown Plank Road Milwaukee, WI 53226
PR:EMAIL                         	bhoffmann@mcw.edu
PR:PHONE                         	414-955-8671
#STUDY
ST:STUDY_TITLE                   	The Influence of Sugar, Artificial Sweeteners, and the Microbiome on Rodent TCA
ST:STUDY_TITLE                   	Concentrations (part I)
ST:STUDY_SUMMARY                 	Targeted TCA concentrations of rodents treated with diets rich in commonly used
ST:STUDY_SUMMARY                 	artifically sweeteners will be assessed in this study. We hypothesized that a
ST:STUDY_SUMMARY                 	specific subset of plasma metabolites are generated as a result from a diet rich
ST:STUDY_SUMMARY                 	in commonly used artificial sweeteners and their subsequent processing by the
ST:STUDY_SUMMARY                 	gut microbiome, which could ultimately lead to impaired glycemic control and
ST:STUDY_SUMMARY                 	negative physiological health outcomes. To test this hypothesis we administered
ST:STUDY_SUMMARY                 	normal, high glucose, fructose, aspartame, and acesulfame potassium diets to
ST:STUDY_SUMMARY                 	rats for 3 weeks, followed by a plasma collection through cardiac puncture and
ST:STUDY_SUMMARY                 	metabolic analysis. We also treated the gut microbiota with in rats with the
ST:STUDY_SUMMARY                 	same diets plus bacitracin/streptomycin to observe how alterations of the
ST:STUDY_SUMMARY                 	microbiome influence the plasma metabolic profile in these animals. The
ST:STUDY_SUMMARY                 	resulting data will give us insights into the influence of high sugar and
ST:STUDY_SUMMARY                 	artificial sweetener diets on homeostatic metabolic processes and dive into the
ST:STUDY_SUMMARY                 	symbiotic relationship of the gut microbiome with this process.
ST:INSTITUTE                     	Mayo Clinic
ST:LAST_NAME                     	Hoffmann
ST:FIRST_NAME                    	Brian
ST:ADDRESS                       	8701 Watertown Plank Road Milwaukee, WI 53226
ST:EMAIL                         	bhoffmann@mcw.edu
ST:PHONE                         	414-955-8671
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Rattus norvegicus
SU:TAXONOMY_ID                   	10116
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	Sample # 1	Group:Group 7	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 2	Group:Group 6	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 3	Group:Group 3	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 4	Group:Group 3	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 5	Group:Group 3	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 6	Group:Group 1	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 7	Group:Group 1	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 8	Group:Group 8	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 9	Group:Group 4	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 10	Group:Group 2	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 11	Group:Group 7	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 12	Group:Group 1	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 13	Group:Group 6	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 14	Group:Group 4	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 15	Group:Group 5	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 16	Group:Group 5	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 17	Group:Group 5	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 18	Group:Group 6	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 19	Group:Group 3	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 20	Group:Group 2	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 21	Group:Group 2	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 22	Group:Group 7	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 23	Group:Group 5	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 24	Group:Group 8	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 25	Group:Group 6	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 26	Group:Group 5	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 27	Group:Group 3	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 28	Group:Group 3	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 29	Group:Group 4	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 30	Group:Group 2	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 31	Group:Group 1	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 32	Group:Group 2	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 33	Group:Group 4	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 34	Group:Group 4	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 35	Group:Group 7	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 36	Group:Group 8	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 37	Group:Group 8	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 38	Group:Group 1	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 39	Group:Group 1	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 40	Group:Group 8	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 41	Group:Group 6	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 42	Group:Group 2	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 43	Group:Group 5	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 44	Group:Group 6	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 45	Group:Group 8	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 46	Group:Group 7	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 47	Group:Group 4	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 48	Group:Group 7	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 49	Group:Group 9	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 50	Group:Group 10	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 51	Group:Group 10	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 52	Group:Group 9	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 53	Group:Group 10	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 54	Group:Group 10	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 55	Group:Group 9	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 56	Group:Group 9	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 57	Group:Group 10	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 58	Group:Group 9	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 59	Group:Group 10	Gender=M; Sample=Plasma; Species=Rat; study=ms6704
SUBJECT_SAMPLE_FACTORS           	-	Sample # 60	Group:Group 10	Gender=F; Sample=Plasma; Species=Rat; study=ms6704
#COLLECTION
CO:COLLECTION_SUMMARY            	"Samples were collected by cardiac puncture and plasma was collected following
CO:COLLECTION_SUMMARY            	standard centrifugation steps. Immediately following the samples were separated
CO:COLLECTION_SUMMARY            	into 500 uL aliquots in 600 uL tubes and frozen in liquid nitrogen.
CO:SAMPLE_TYPE                   	Blood (plasma)
#TREATMENT
TR:TREATMENT_SUMMARY             	"We administered normal, high glucose, aspartame, and acesulfame potassium diets
TR:TREATMENT_SUMMARY             	to rats for 3 weeks, followed by a plasma collection through cardiac puncture
TR:TREATMENT_SUMMARY             	and metabolic analysis (Group 1-4 samples). We also treated the gut microbiota
TR:TREATMENT_SUMMARY             	with in rats with the same diets plus bacitracin/streptomycin to observe how
TR:TREATMENT_SUMMARY             	alterations of the microbiome influence the plasma metabolic profile in these
TR:TREATMENT_SUMMARY             	animals (Groups 5-8). The samples here contain the fructose diet group (Group
TR:TREATMENT_SUMMARY             	9). We also treated the gut microbiota with in rats with the same diets plus
TR:TREATMENT_SUMMARY             	bacitracin/streptomycin to observe how alterations of the microbiome influence
TR:TREATMENT_SUMMARY             	the plasma metabolic profile in these animals (Groups 5-8). The samples here
TR:TREATMENT_SUMMARY             	contain the fructose diet group with antibiotic (Group 10). For the gut
TR:TREATMENT_SUMMARY             	microbiota experiment, during the last 10 days of the diet subsets of all groups
TR:TREATMENT_SUMMARY             	will have bacitracin and streptomycin (B/S) provided in their drinking water
TR:TREATMENT_SUMMARY             	(0.5g/250 mL). The resulting data will give us insights into the influence of
TR:TREATMENT_SUMMARY             	high sugar and artificial sweetener diets on homeostatic metabolic processes and
TR:TREATMENT_SUMMARY             	dive into the symbiotic relationship of the gut microbiome with this process.
TR:TREATMENT_SUMMARY             	Group1 = normal diet Group2 = high glucose diet Group3 = aspartame diet Group4 =
TR:TREATMENT_SUMMARY             	acesulfame potassium diet Group5 = rat gut microbiota normal diet + antibotics
TR:TREATMENT_SUMMARY             	Group6 = rat gut microbiota high glucose diet + antibotics Group7 = rat gut
TR:TREATMENT_SUMMARY             	microbiota aspartame diet + antibotics Group8 = rat gut acesulfame potassium
TR:TREATMENT_SUMMARY             	diet + antibotics Group9 = fructose diet Group10 = rat gut fructose diet +
TR:TREATMENT_SUMMARY             	antibotics"
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	TCA Concentrations
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	GC
CH:INSTRUMENT_NAME               	Agilent 7890B
CH:COLUMN_NAME                   	Agilent HP5-MS (30m × 0.25mm, 0.25 um)
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:MS_COMMENTS                   	-
MS:INSTRUMENT_NAME               	Agilent 5977A
MS:INSTRUMENT_TYPE               	Single quadrupole
MS:MS_TYPE                       	EI
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	uM
MS_METABOLITE_DATA_START
Samples	Sample # 1	Sample # 2	Sample # 3	Sample # 4	Sample # 5	Sample # 6	Sample # 7	Sample # 8	Sample # 9	Sample # 10	Sample # 11	Sample # 12	Sample # 13	Sample # 14	Sample # 15	Sample # 16	Sample # 17	Sample # 18	Sample # 19	Sample # 20	Sample # 21	Sample # 22	Sample # 23	Sample # 24	Sample # 25	Sample # 26	Sample # 27	Sample # 28	Sample # 29	Sample # 30	Sample # 31	Sample # 32	Sample # 33	Sample # 34	Sample # 35	Sample # 36	Sample # 37	Sample # 38	Sample # 39	Sample # 40	Sample # 41	Sample # 42	Sample # 43	Sample # 44	Sample # 45	Sample # 46	Sample # 47	Sample # 48	Sample # 49	Sample # 50	Sample # 51	Sample # 52	Sample # 53	Sample # 54	Sample # 55	Sample # 56	Sample # 57	Sample # 58	Sample # 59	Sample # 60
Factors	Group:Group 7	Group:Group 6	Group:Group 3	Group:Group 3	Group:Group 3	Group:Group 1	Group:Group 1	Group:Group 8	Group:Group 4	Group:Group 2	Group:Group 7	Group:Group 1	Group:Group 6	Group:Group 4	Group:Group 5	Group:Group 5	Group:Group 5	Group:Group 6	Group:Group 3	Group:Group 2	Group:Group 2	Group:Group 7	Group:Group 5	Group:Group 8	Group:Group 6	Group:Group 5	Group:Group 3	Group:Group 3	Group:Group 4	Group:Group 2	Group:Group 1	Group:Group 2	Group:Group 4	Group:Group 4	Group:Group 7	Group:Group 8	Group:Group 8	Group:Group 1	Group:Group 1	Group:Group 8	Group:Group 6	Group:Group 2	Group:Group 5	Group:Group 6	Group:Group 8	Group:Group 7	Group:Group 4	Group:Group 7	Group:Group 9	Group:Group 10	Group:Group 10	Group:Group 9	Group:Group 10	Group:Group 10	Group:Group 9	Group:Group 9	Group:Group 10	Group:Group 9	Group:Group 10	Group:Group 10
Lactate	1038	1600	3623	3607	2208	2102	1926	1495	1549	4676	1189	3393	1267	1520	1406	1633	2296	1099	1529	2621	1836	2343	2615	1342	2161	1524	1823	2157	3048	2410	3026	2450	2441	3013	1968	1535	2844	3520	2802	2360	1900	2553	1530	1692	1764	1690	2908	2572	3759	1553	2222	1956	1417	2244	2541	2967	2744	3144	1282	2726
Succinate	4.25	13.34	28.45	17.47	14.67	10.50	8.20	10.11	8.71	63.82	11.85	19.64	7.10	10.79	8.80	6.63	6.85	5.50	12.64	5.13	9.08	17.16	13.53	9.97	12.50	5.98	8.70	13.84	8.16	13.60	17.79	15.24	9.87	18.96	10.44	11.28	44.50	12.84	13.26	15.20	11.36	10.82	10.68	6.61	8.01	14.17	7.96	11.58	12.35	4.60	7.13	8.62	5.19	6.71	6.39	9.00	6.94	11.95	4.96	5.14
Fumarate	6.09	9.14	9.15	7.57	7.15	6.94	5.09	6.74	5.64	8.39	6.65	7.35	5.44	5.24	4.04	4.44	4.29	3.75	5.81	4.71	4.01	7.04	5.01	4.73	6.02	4.64	7.05	7.09	4.55	7.95	8.12	8.98	5.52	7.99	6.90	7.33	16.77	7.55	8.30	9.11	6.14	5.74	5.61	4.66	4.94	8.57	4.94	6.84	4.72	2.32	4.11	6.13	3.20	4.14	4.08	6.10	4.74	6.66	2.81	3.62
Oxaloacetate	0.3	0.7	0.6	1.2	0.5	0.7	0.5	0.4	0.5	0.5	0.5	0.5	1.6	0.4	0.4	0.6	0.6	0.4	0.5	0.7	0.5	0.4	0.4	0.5	0.5	0.5	0.6	0.4	0.4	0.5	0.5	0.5	0.5	0.6	0.5	0.5	0.6	0.7	0.8	0.4	0.5	0.4	0.3	0.4	0.5	0.4	0.5	0.6	0.4	0.4	0.4	0.5	0.4	0.4	0.4	0.5	0.5	0.5	0.4	0.5
Ketoglutarate	6.3	14.0	16.1	18.0	16.9	21.5	8.8	13.6	15.3	17.4	15.1	17.9	13.0	13.6	9.8	12.8	11.0	12.0	15.6	13.0	11.8	15.4	12.3	12.4	14.6	14.8	20.2	15.5	12.9	16.9	22.0	18.5	12.2	20.1	18.1	16.7	14.3	22.1	22.1	19.4	13.6	15.1	12.8	12.4	11.5	21.3	13.2	19.2	11.6	12.1	12.5	17.4	9.3	11.1	11.5	16.7	14.4	15.9	12.1	12.5
Malate	8.6	20.0	24.3	22.7	21.5	23.5	12.5	21.5	19.4	30.6	23.5	28.2	13.9	18.4	12.2	14.8	14.7	12.3	21.0	16.1	14.1	27.4	18.3	17.6	19.6	13.1	21.7	22.2	14.5	25.3	26.5	28.6	18.1	25.6	23.4	25.0	17.6	25.7	27.9	29.6	18.1	18.3	17.4	15.5	16.3	30.3	16.5	23.7	13.3	5.7	12.4	18.7	8.8	12.7	12.1	17.6	12.9	18.5	6.5	10.7
Aspartate	6.6	9.8	9.6	11.3	9.5	14.7	7.7	9.7	8.2	7.9	7.6	12.2	8.6	9.3	11.5	6.5	7.5	6.5	12.7	12.5	7.5	6.4	10.0	7.9	15.6	6.4	10.9	11.0	8.3	11.0	10.2	9.0	15.6	9.5	8.1	9.0	10.6	18.5	15.6	9.8	8.8	7.9	7.7	13.1	14.1	10.5	12.4	15.9	10.4	7.8	8.4	9.9	4.6	9.8	10.1	9.0	6.3	13.9	5.7	7.6
2-Hydroxyglutarate	0.70	1.25	1.60	1.09	1.17	1.38	0.70	1.34	1.24	1.57	1.29	1.50	1.50	1.13	1.74	1.29	1.36	0.83	1.23	1.05	0.81	1.23	1.48	0.97	1.24	1.17	1.32	1.48	1.09	1.44	1.57	1.56	1.10	1.36	1.38	1.36	3.04	1.65	1.55	1.66	1.10	1.15	1.30	1.22	1.13	1.51	1.10	1.32	0.89	0.71	1.00	1.12	0.69	0.93	0.86	1.29	1.53	1.22	0.62	0.98
Glutamate	31.1	43.4	45.4	71.3	61.3	76.4	37.2	43.3	47.7	41.3	34.1	60.6	36.6	50.4	50.2	32.0	30.1	30.2	52.1	74.7	41.9	35.1	34.9	33.3	62.4	35.0	57.0	50.4	57.4	57.8	53.3	49.1	66.8	51.9	37.8	40.8	48.7	93.7	75.2	47.5	34.9	49.2	31.1	61.5	61.2	42.8	58.3	69.4	56.5	53.7	44.3	47.7	25.9	54.5	56.1	47.4	33.1	68.6	33.3	46.4
cis-Aconitic Acid	8.9	14.5	15.1	12.6	11.2	13.4	8.8	15.1	11.1	18.7	12.1	12.3	9.5	9.7	3.9	6.5	6.5	6.4	12.0	11.9	6.7	5.6	8.7	9.0	11.6	5.7	11.4	10.8	7.9	15.4	15.7	15.7	12.9	8.6	12.7	10.2	9.8	16.5	11.9	16.2	12.6	7.6	13.0	7.4	10.2	11.0	9.6	9.9	11.0	6.2	12.8	9.3	6.8	15.7	7.4	9.3	11.8	10.6	5.2	9.7
Citrate	130	244	316	306	245	327	207	247	291	336	243	316	246	270	207	231	203	197	269	258	198	266	273	213	246	240	297	309	290	343	321	347	279	270	266	264	267	339	314	284	235	323	273	249	254	289	286	259	298	257	279	270	206	252	232	371	293	325	195	289
Isocitrate	4.34	6.52	6.79	9.29	5.90	5.51	6.97	5.04	5.34	7.58	4.08	7.24	4.03	5.45	5.03	5.75	5.90	2.89	5.99	5.44	4.17	4.99	6.51	4.55	3.97	3.84	4.56	4.34	4.44	5.44	5.53	7.34	4.53	3.39	4.07	3.98	4.23	6.50	5.30	4.42	3.31	7.53	4.29	3.19	3.40	4.36	4.58	4.35	4.94	3.86	5.35	4.20	3.71	4.95	3.58	5.67	4.34	5.96	3.54	6.33
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name
Lactate
Succinate
Fumarate
Oxaloacetate
Ketoglutarate
Malate
Aspartate
2-Hydroxyglutarate
Glutamate
cis-Aconitic Acid
Citrate
Isocitrate
METABOLITES_END
#END